News from CRG
Researchers from the EU-funded BLUEPRINT project join their international colleagues this week at the 2016 International Human Epigenome Consortium (IHEC) conference in Brussels to report the latest results in understanding blood cell development and blood disease.
BLUEPRINT received €30 million from the European Union to decipher the role of epigenetics in normal and diseased blood cells. Epigenetic effects alter the activity of genes without altering the DNA code, and play an important role in development and disease.
The conference held in Brussels on 8-9 September 2016 marks the final stage of the BLUEPRINT project. “BLUEPRINT has produced more new science and more understanding of blood cell disease than we could have imagined at the outset,” says BLUEPRINT coordinator Professor Hendrik Stunnenberg from Radboud University, Nijmegen, The Netherlands.
BLUEPRINT was officially launched on 1 October 2011. With the principal funding of €30 million by the European Union the project has been the European cornerstone of the international research cooperation effort IHEC, bringing together organisations and researchers from across the globe. At the CRG, four principal investigators are participating in this project including Xavier Estivill, Roderic Guigó and Stephan Ossowski at the Bioinformatics and Genomics programme, Thomas Graf at the Gene Regulation, Stem Cells and Cancer programme, as well as Ivo Gut at the CNAG-CRG.